论文部分内容阅读
目的 观察微粒化非诺贝特对Ⅳ型高脂血症患者纤溶活性的影响。方法 2 8例患者口服微粒化非诺贝特 8wk(2 0 0mg,每晚 1粒 ) ,用药前、后检测血清TG、TC、HDL C、LDL C、apoAI、apoB、LP (a)及t PA、PAI 1、PIg ,D D水平。 结果 微粒化非诺贝特治疗后 ,血清TG水平显著降低 ,HDL C ,apoAI水平升高 ,TC、LDL C、apoB和LP(a)水平在治疗过程中没有明显改变。t PA及PIg水平较用药前均有所上升 ,而PAI 1水平则显著下降 (P <0 .0 5 )。结论 微粒化非诺贝特能明显降低Ⅳ型高脂血症患者血浆TG水平 ,并升高HDL C水平 ,同时能改变患者的纤溶活性
Objective To investigate the effect of micronized fenofibrate on fibrinolytic activity in type Ⅳ hyperlipidemia. Methods Twenty-eight patients underwent oral microencapsulation of fenofibrate for 8 weeks (200 mg once daily). Serum TG, TC, HDL C, LDL C, apoAI, apoB, LP (a) and t PA, PAI 1, PIg, DD levels. Results After treatment with micronized fenofibrate, the levels of serum TG, HDL C, apoAI and TC, LDL C, apoB and LP (a) did not change significantly during treatment. t PA and PIg levels increased compared with before treatment, while PAI 1 level decreased significantly (P <0.05). Conclusion Micronized fenofibrate can significantly reduce the level of plasma TG in patients with type Ⅳ hyperlipidemia and increase the level of HDL C, meanwhile, it can change the fibrinolytic activity